|
KMID : 0363220060440121410
|
|
Korean Journal of Dermatology
2006 Volume.44 No. 12 p.1410 ~ p.1416
|
|
|
The Effects of 5% Imiquimod Cream on Bowen`s Disease
|
|
Ko Hyun-Chang
Oh Chang-Keun
Kim Sung-Jun
Kim Byung-Soo
Jang Bong-Seok
Kim Moon-Bum
Kwon Kyung-Sool
|
|
|
Abstract
|
|
|
Background: Imiquimod is an immune response modifier which works as a Toll-like receptor 7 agonist which induces interferon and other cytokines through the innate immune system and stimulates cell-mediated immunity through T cells. Imiquimod has been shown to be efficacious as a topical treatment for variable cutaneous neoplasms including Bowen’s disease.
Objective: The purpose of this study was to evaluate the efficacy and safety of 5% imiquimod cream for the treatment of Bowen’s disease.
Methods: Thirty one lesions from 13 patients with Bowen’s disease were treated with 5% imiquimod cream, 3 times per week at night, until complete clearance of lesions had occurred. During the follow-up period, the duration of therapeutic response, clearance rate, side effects and recurrence were recorded. Biopsy specimens from five patients after treatment completion were obtained to confirm tumor clearance.
Results: Complete clinical response was obtained in 30 lesions (96.8%) from 12 patients, and a partial clinical response was observed in a palmar lesion of 1 patient. The duration of complete response ranged from 4 to 24 weeks, and mean duration was 11.8 weeks. All patients showed mild to moderate local skin reactions such as erythema, erosion, crusting, itching, burning, and pain. No-one experienced systemic adverse effects during topical application. After 3 to 26 months follow-up of the patients who had shown complete clearance, no-one encountered recurrence.
Conclusion: 5% imiquimod cream appears to be safe and effective for the treatment of Bowen’s disease, and so therefore may be promising future treatment for this condition.
|
|
|
KEYWORD
|
|
|
Bowen`s disease, Imiquimod
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|